The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
There will be a U.K. contract for this will there? Or will it be up to each individual travelling to get a pcr test from any number of companies offering pcr tests. All of this “there will be loads of contracts” noise no one can explain what why or where these contracts will be
Lateral flow tests with symptoms accuracy over 95%. They are also cheap and results in minutes with no need for additional pcr equipment. PCR tests are not practical, to think that everyone entering the U.K. will get a PCR test is ludicrous.
I totally agree outcome of dhsc dispute is huge, instantly doubles company value with cash in the bank. But I don’t see where these government or airport contracts will come from in the U.K. I don’t know what tests they use in China but I presume they are cheaper than Nova’s - where are their contracts coming from? There are cheap lateral flow tests available with similar accuracy to pcr now.
Pleased to see a recovery here but concerns that this is based purely on speculation. Arrivals from China will need to show proof of negative test (which they will buy and get in China from Chinese manufacturers presumable not from Nova) or need proof of full vaccine as per Spanish guidance. I’m not sure where the benefit is here for Nova? Why will they suddenly be getting U.K. contracts when the test will need to be done prior to departure in China?
The RNS stated little or no value but it’s didn’t state 50% less value!!
Not sure that’s quite true. If the company/business outside of covid was worth 12p then any investor offered an opportunity to buy at 5p would have been doing so at a huge discount. Or actually the company wasn’t worth enough of a return at a price of 5p which is more likely.
Surprised that people are speculating about a takeover bid at 12p+ when the company couldn’t complete a raise with potential investors at 5p
I think it’s probably both actually - unknown interaction of using steroids with inhaled beta interferon seemingly reducing its efficacy combined with better treatment in the placebo group which reduced the severity of their disease anyway which meant the potential benefits of interferon are reduced when compared to the placebo group
Took some this morning at just under 17p. Averaged down without much risk and I can see a considerable upside from here. US results to come, £25m in the bank. Increased profile in the U.K. and USA and advanced the R&D of inhaled beta interferon exponentially compared to pre covid.
Not the results we wanted from the Sprinter trial and undoubtedly there will be a sell off this morning - if Polygon hold that will be reassuring especially with the US home use trial results yet to come in. Bare in mind the covid situation in the US is worse than here the results could be very different. Worth holding for those or selling at significant loss today that’s the question.
Have to say that I am disappointed with the update this morning re timelines. US FDA approval for emergency use could take some time to be granted and there are already a number of other companies with this approval and selling in the US already. End of July timeline for EU CE mark approval for home use - further studies required. I had hoped that by this point we would be further ahead.
Thoughts on the impact of the listing tomorrow? Suspect there will be some buying pressure first thing before the US markets open in the afternoon. Hard to tell whether the listing is going to have an immediate impact or if it’ll be steady until actual business news